MELBOURNE, AUSTRALIA – MedAdvisor Limited (ASX:MDR), an Australia software developer focused on improving health outcomes by placing patients at the centre of connected health platforms, has announced the signing of a memorandum of understanding with Epilepsy Queensland Inc.
In a disclosure to the Australian Securities Exchange, MedAdvisor Limited said the agreement will see the software developer and Epilepsy Queensland Inc collaborating to help improve personal medication management of epilepsy patients and their carers by promoting the use of MedAdvisor’s free medication management app.
Epilepsy is the world’s most common serious brain disorder with nearly 3.5% of Australians affected by the disorder. About 800,000 people in the country will be diagnosed with epilepsy at some stage in life.
Epilepsy Queensland’s key goals are to increase awareness of epilepsy in the community and support people with epilepsy.
MedAdvisor has created a software platform that helps individuals to monitor their medication use, connecting to their pharmacy of choice, automatically retrieving medication records and activating an intelligent training, information and reminder system to ensure correct and reliable medication use, the company disclosed.
“In Australia, medication adherence in epilepsy is typically quite low, with just 60% of medication doses taken as prescribed. We are pleased to be working with Epilepsy Queensland to assist epilepsy patients and their carers manage their medication safely and effectively,” said MedAdvisor CEO Robert Read.
For her part, Epilepsy Queensland CEO Helen Whitehead said: “We are excited about working closely with MedAdvisor during 2016. We believe the MedAdvisor app is an important innovation that will help patients and their carers to make a measurable difference to health outcomes for people with epilepsy. The app will facilitate some tailored information that will help bring epilepsy out of the shadows and we look forward to promoting it to our community”. – BusinessNewsAsia.com